- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
DrugsDisclosed.com Launches ‘Medication Trustpilot’ to Amplify Patient Voices
Review platform launches in light of new research which reveals that 93% lack trust in pharma companies.
DrugsDisclosed.com launched today to give patients more control over their own treatments to share real world experiences of their medicines. Alongside today’s launch, new research underlines the need for pharmaceutical companies to better listen and learn from these experiences — with a ‘trust deficit’ opening up between patients and the industry that develops and produces their medicines.
DrugsDisclosed.com is a review platform that offers patients the chance to quickly share and compare their experiences with others using the same medications. The site collates data from over 352,044 unique patient medication reviews from the associated DrugStars medication management app.
Trust deficit
The need for patients to be heard is confirmed in research commissioned by DrugsDisclosed.com and market research partner Userneeds. Results reveal that patients feel ignored once medicines go to market and regard pharmaceutical companies with suspicion. The survey of more than a thousand users of prescription and over the counter (OTC) medicines from the UK and Ireland revealed:
- 93% of patients do not trust advice from pharmaceutical companies about their medication
- 84% feel the pharmaceutical industry influences prescription decisions
- 68% expressed a desire to be able to feedback their experiences to pharma companies
- 81% of patients do not feel listened to by pharmaceutical companies
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
